

## **EORTC GCG 55994**

Randomized phase III study of neoadjuvant CT followed by surgery vs. concomitant RTX+CT in FIGO stage Ib2, IIa > 4 cm or IIb cervical cancer.

---

Trial setting: FIGO stage Ib2, IIa > 4 cm or IIb cervical cancer

Study Design: Randomized unblinded 2-arm randomized phase III

Sponsor(s): EORTC GCG

Planned No. of patients: 626 pts (reached in June 2014)

Other important information:

- Primary end-point: OS at 5 years → study closure foreseen at January 2019.
- Data collection and cleaning ongoing.
- No interim analysis foreseen.
- Early publications on trial and treatment characteristics (not related to efficacy):
  - Short term toxicity (presented at IGCS 2016, updated for BGCS 2017)
  - Treatment characteristics (presented at IGCS 2016, updated for BGCS 2017)